Stockscreener 앱 받기
13.79
1.10%
0.15
시간 외 거래:
13.79
Eyepoint Inc 주식(EYPT)의 최신 뉴스
Behavioral Patterns of EYPT and Institutional Flows - Stock Traders Daily
Eyepoint Pharmaceuticals pursues new therapies as anti-VEGF treatments fall short for DME patients - Traders Union
EyePoint (EYPT) surges 15.2%: Is this an indication of further gains? - MSN
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2025 earnings call transcript - MSN
Risk Hedge: What is the long term forecast for EyePoint Pharmaceuticals Inc stock2026 Geopolitical Influence & Safe Entry Point Identification - baoquankhu1.vn
EyePoint Pharmaceuticals Q4 2025 earnings preview - MSN
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter - The Motley Fool
This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment - AOL.com
Insider Buying: Eyepoint Pharmaceuticals (NASDAQ:EYPT) CEO Buys 1,500 Shares of Stock - MarketBeat
Eyepoint (EYPT) CEO Duker buys $19,723 in company stock - Investing.com
EyePoint’s COMO Phase 3 Trial Puts Long-Acting DME Strategy in Focus - TipRanks
Guggenheim reiterates EyePoint stock rating on Duravyu safety data By Investing.com - Investing.com Canada
Guggenheim reiterates EyePoint stock rating on Duravyu safety data - Investing.com
EyePoint (EYPT) Issues Stock Options to New Employees as Hiring Incentives - GuruFocus
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
EyePoint gives new hires 20,000 stock options, $13.20 strike - Stock Titan
Earnings call transcript: Eyepoint Pharmaceuticals Q4 2025 reveals revenue drop - Investing.com Nigeria
Parkman Healthcare Partners Acquires New Stake in EyePoint Pharmaceuticals - Intellectia AI
Suvretta Capital Management LLC Sells 611,376 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
Rosalind Advisors Inc. Acquires Shares of 650,000 Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Chardan raises EyePoint stock price target to $29 on cash position - Investing.com Nigeria
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 9.1%Here's Why - MarketBeat
Jefferies Financial Group Inc. Purchases Shares of 140,000 Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
Winners Losers: Should I hold or sell EyePoint Pharmaceuticals Inc now2026 Review & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
EyePoint files automatic mixed securities shelf - MSN
H.C. Wainwright raises EyePoint stock price target to $30 on DME trial progress - Investing.com Nigeria
J.P. Morgan Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT) - The Globe and Mail
Aug Breakouts: Can EyePoint Pharmaceuticals Inc expand its profit margins2026 Intraday Action & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
EyePoint Pharmaceuticals (EYPT) Receives a Buy from Mizuho Securities - The Globe and Mail
EyePoint Pharmaceuticals Experiences Evaluation Revision Amidst Market Dynamics and Performance Fluctuations - Markets Mojo
EyePoint (EYPT) Sees Target Price Raise by Citigroup to $35 | EY - GuruFocus
Citigroup Boosts Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target to $35.00 - MarketBeat
EyePoint stock rating maintained at Outperform by Mizuho - Investing.com
EyePoint stock rating maintained at Outperform by Mizuho By Investing.com - Investing.com South Africa
What is HC Wainwright's Estimate for EYPT Q1 Earnings? - MarketBeat
EyePoint Reports Fourth-Quarter and Full-Year 2025 Financial Results, Provides Corporate Update - VisionMonday.com
(EYPT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates - MSN
Eyepoint Pharmaceuticals, Inc. $EYPT Holdings Trimmed by Blue Owl Capital Holdings LP - MarketBeat
EyePoint (EYPT) Q4 2025 Earnings Call Transcript - AOL.com
EyePoint (EYPT) CFO gifts 10,000 shares, including family trust holdings - Stock Titan
Decoding EyePoint Inc (EYPT): A Strategic SWOT Insight - GuruFocus
Is It Too Late To Consider EyePoint (EYPT) After Its 173% One Year Surge? - Yahoo Finance
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target Raised to $30.00 - MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2025 Earnings Call Transcript - Insider Monkey
Chardan Raises Price Target on EyePoint Pharmaceuticals to $29 From $27, Keeps Buy Rating - marketscreener.com
EyePoint (EYPT) Analyst Rating Update: Price Target Increased to $30 | EYPT Stock News - GuruFocus
EyePoint: The 'Pre-Readout' Surge Is Hiding A Commercial Reality Check (NASDAQ:EYPT) - Seeking Alpha
Chardan Capital Raises Price Target for EYPT to $29.00, Maintains Buy Rating | EYPT Stock News - GuruFocus
Earnings Summary: EyePoint (EYPT) Q4 2025 net loss widens - AlphaStreet
Is It Too Late To Consider EyePoint (EYPT) After A 1‑Year Surge And DCF Upside? - simplywall.st
EyePoint Q4 2025 Financial Results: Net Loss of $67.6MNews and Statistics - IndexBox
EyePoint: Fourth Quarter Financial Results Overview - Bitget
1.20%
0.06%
자본화:
|
볼륨(24시간):